Tissue-type plasminogen activator: Characteristics, applications and production technology

Biotechnology Advances

Volumn 14, Issue 3, 1996, Pages 239-266

  Rouf, S A ^a   Moo Young, M ^a   Chisti, Y ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

fibrinolysis; myoca rdial infarction; streptokinase; thrombolytics; thrombosis; Tissue plasminogen activator; urokinase

Indexed keywords

AGENTS; BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; CARDIOLOGY; PATIENT TREATMENT;

FIBRINOLYSIS; MYOCARDIAL INFARCTION; STREPTOKINASE; THROMBOLYTICS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

ENZYMES;

EID: 0030454399     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/0734-9750(96)00019-5     Document Type: Review

References (64)

1. 1. Kok, P. and Astrup, T. (1969) Biochemistry, 8: 79-86. Isolation and purification of a tissue plasminogen activator and its comparison with urokinase.
2. 2. Butler, M. (1987) Animal Cell Technology, Open University Press, London, pp. 129-144. Plasminogen activators.
3. 3. Rånby, M., Bergsdorf, N., Pohl, G. and Wallén, P. (1982) FEBS Letts., 146: 289-296. Isolation of two variants of native one-chain tissue plasminogen activator.
4. 4. Griffiths, J. B. and Electricwala, A. (1987) Advances in Biochemical Engineering/Biotechnology, 34: 147-166. Production of tissue plasminogen activators from animal cells.
5. 5. Klausner, A. (1986) Biotechnology, 4; 706-711. Researchers probe second-generation tPA.
6. 6. Datar, R. V., Cartwright, T. and Rosen, C. -G. (1993) Biotechnology, 11: 349-357. Process economics of animal cell and bacterial fermentations: a case study analysis of tissue plasminogen activator.
7. 7. Pohl, G., Källström, M., Bergsdorf, N., Wallén, P. and Jörnvall, H. (1984) Biochemistry, 23: 3701-3707. Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences.
8. 8. Kluft, C., van Wezel, A. L., van der Velden, C. A. M., Emeis, J. J., Verheijen, J. H. and Wijngaards, G. (1983) Advances in Biotechnological Processes, 2: 97-110, Alan R. Liss, New York. Large-scale production of extrinsic (tissue-type) plasminogen activator from human melanoma cells.
9. 9. Albrechtsen, O. K. (1957) Br. J. Haematol., 3: 284-291. The fibrinolytic activity of human tissues.
10. 10. Electricwala, A. and Atkinson, T. (1985) Eur. J. Biochem., 147: 511-516. Purification and properties of plasminogen activators from epithelial cells.
11. 11. Kadouri, A. and Bohak, Z. (1985) Advances in Biotechnological Processes, 5: 275-299, Alan R. Liss, New York. Production of plasminogen activator by cells in culture.
12. 12. Levin, E. G. (1986) Blood, 67: 1309-1313. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells.
13. 13. Lubiniecki, A., Arathoon, R., Polastri, G., Thomas, J., Wiebe, M., Garnick, R., Jones, A., van Reis, R. and Builder, S. (1989) In Advances in Animal Cell Biology and Technology for Bioprocesses, Spier, R. E., Griffiths, J. B., Stephenne, J. and Crooy, P. J., editors, Butterworths, London, pp. 442-451. Selected strategies for manufacture and control of recombinant tissue plasminogen activator prepared from cell culture.
14. 14. Cartwright, T. (1992) In Animal Cell Biotechnology, vol. 5, Spier, R. E. and Griffiths, J. B., editors, Academic Press, New York, pp. 217-245. Production of tPA from animal cell culture.
15. 15. Chisti, Y. and Moo-Young, M. (1991) In Biotechnology: The Science and the Business, Moses, V. and Cape, R. E., editors, Harwood Academic Publishers, New York, pp. 167-209. Fermentation technology, bioprocessing, scale-up and manufacture.
16. 16. Chisti, Y. (1989) Airlift Bioreactors, Elsevier Applied Science, New York, pp. 355.
17. 17. Cartwright, T. and Crespo, A. (1991) In Production of Biologicals from Animal Cells in Culture, Spier, R. E., Griffiths, J. B. and Meignier, B., editors, Butterworth-Heinemann, London, pp. 669-694. Production of a pharmaceutical enzyme: animal cells or E. coli?
18. 18. Chisti, Y. (1993) Bioproc. Eng., 9: 191-196. Animal cell culture in stirred bioreactors: observations on scale-up.
19. 19. Tung, A. S., Sample, J. G., Brown, T. A., Ray, N. G., Hayman, E. G. and Runstandler, P. W. (1988) Biopharmacology, 1: 50-58. tPA production through mass culture of Chinese hamster ovary cells.
20. 20. Tyo, M. A., Bulbulian, B. J., Menken, B. Z. and Murphy, T. J. (1988) In Animal Cell Biotechnology, vol. 3, Spier, R. E. and Griffiths, J. B., editors, Academic Press, New York, pp. 357-371. Large scale mammalian cell culture utilizing Acusyst technology.
21. 21. Berg, G. J. and Bodeker, B. G. D. (1988) In Animal Cell Biotechnology, vol. 3, Spier, R. E. and Griffiths, J. B., editors, Academic Press, New York, pp. 322-335. Employing a ceramic matrix for the immobilization of animal cells in culture.
22. 22. Källström, U., Chatzisávido, N., Buzsaky, F. and Lindner-Olsson, E. (1991) In Production of Biologicals from Animal Cells in Culture, Spier, R. E., Griffiths, J. B. and Meignier, B., editors, Butterworth-Heinemann, London, pp. 745-747. Optimization of tPA production in a 3 L continuous perfusion bioreactor.
23. 23. Nilsson, K., Birnbaum, S. and Mosbach, K. (1988) Appl. Microbiol. Biotechnol., 27: 366-371. Microcarrier culture of recombinant Chinese hamster ovary cells for production of human immune interferon and human tissue-type plasminogen activator.
24. 24. Takagi, M., Kiyota, T. and Ueda, K. (1994) J. Ferment. Bioeng., 78: 269-271. Effect of insoluble medium component on the productivity of tissue plasminogen activator by cells on microcarriers.
25. 25. Takagi, M., Okumura, H., Okada, T., Kobayashi, N., Kiyota, T. and Ueda, K. (1994) J. Ferment. Bioeng., 77: 301-306. An oxygen supply strategy for the large-scale production of tissue plasminogen activator by microcarrier cell culture.
26. 26. Takagi, M. and Ueda, K. (1994) J. Ferment. Bioeng., 77: 655-658. On-line determination of optimum time for switching from growth phase to production phase in tissue plasminogen activator production in a microcarrier cell culture.
27. 27. Chisti, Y. and Moo-Young, M. (1994) Trans. 1. Chem. E., 72C: 92-94. Anchorage dependent animal cell culture in packed beds with airlift driven liquid circulation: A theoretical analysis of oxygen transfer and comparison with stirred tank microcarrier culture system.
28. 28. Chisti, Y. (1992) Chem. Eng. Progress, 88(1): 55-58. Build better industrial bioreactors.
29. 29. Chisti, Y. (1992) Chem. Eng. Progress, 88(9): 80-85. Assure bioreactor sterility.
30. 30. Kruithof, E. K. O., Schleuning, W. -D. and Bachmann, F. (1985) Biochem. J., 226: 631-636. Human tissue-type plasminogen activator.
31. 31. Brouty-Boye, G. C., Maman, M., Marian, J. -C. and Choay, P. (1984) Biotechnology, 2: 1058-1062. Biosynthesis of human tissue-type plasminogen activator by normal cells.
32. 32. Bykowska, K., Rijken, D. C. and Collen, D. (1981) Thromb. Haemostas., 46: 642-644. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.
33. 33. Einarsson, M., Brandt, J. and Kaplan, L. (1985) Biochim. Biophys. Acta., 830: 1-10. Large-scale purification of human tissue-type plasminogen activator using monoclonal antibodies.
34. 34. Wallén, P., Pohl, G., Bergsdorf, N., Rånby, M., Ny, T. and Jörnvall, H (1983) Eur. J. Biochem., 132: 681-686. Purification and characterization of a melanoma cell plasminogen activator.
35. 35. Clarke, J., Griffiths, J. B., Melling, J., Ling, R., Atkinson, A. and Electricwala, A. (1989) In Advances in Animal Cell Biology and Technology for Bioprocesses, Spier, R. E., Griffiths, J. B., Stephenne, J. and Crooy, P. J., editors, Butterworths, London, pp. 437-441. Comparison of the effects of concanavalin A and derivatives on tissue plasminogen activator production by epithelial and melanoma cell lines.
36. 36. Electricwala, A. (1987) In Biotechnology in Clinical Medicine, Albertini, A., Lenfant, C. and Paoletti, R., editors, Raven Press, New York, pp. 115-125. Production and isolation of tissue plasminogen activator.
37. 37. McIntire, L. V., Diamond, S. L., Nollert, M. U., Carosi, J. A. and Eskin, S. G. (1991) Annals of Biomedical Engineering, 19: 576. Effect of mechanical strain and fluid flow on endothelial cell metabolism.
38. 38. Chisti, Y. and Moo-Young, M. (1994) I. Chem. E. Symp. Ser., 137: 135-146. Separation techniques in industrial bioprocessing.
39. 39. Lemontt, J. F., Wei, C. -M. and Dackowski, W. R. (1985) DNA, 4: 419-428. Expression of active human uterine tissue plasminogen activator in yeast.
40. 40. Chisti, Y. and Moo-Young, M. (1986) Enz. Microbial Technol., 8: 194-204. Disruption of microbial cells for intracellular products.
41. 41. Upshall, A., Kumar, A. A., Bailey, M. C., Parker, M. D., Favreau, K. P., Lewison, M. A., Joseph, M. L., Maraganore, J. M. and McKnight, G. L. (1987) Biotechnology, 5: 1301-1304. Secretion of active human tissue plasminogen activator from the filamentous fungus Aspergillus nidulans.
42. 42. Oka, M., Johansen, H., Okita, B., Wilson, B., Carr, S., Roberts, G., Chen, T., Strickler, J. and Mai, S. (1989) In Advances in Animal Cell Biology and Technology for Bioprocesses, Spier, R. E., Griffiths, J. B., Stephenne, J. and Crooy, P. J., editors, Butterworths, London, pp. 465-471. Purification and characterization of human tPA produced in Drosophila cells.
43. 43. Oka, M. S., Fong, K. -L. L., Carr, S. A. and Shebuski, R. (1990) In Trends in Animal Cell Culture Technology, Murakami, H., editor, Kodansha, Tokyo, pp. 161-166. Characterization and biological properties of recombinant tPA produced in Drosophila cells culture.
44. 44. Rexroad Jr, C. E. (1995) Chem. Ind. (Lond.), 10: 372-375. Transgenic livestock in agriculture and medicine.
45. 45. Schleuning, W. (1987) In Biotechnology in Clinical Medicine, Albertini, A., Lenfant, C. and Paoletti, R., editors, Raven Press, New York, pp. 105-113. The present status of tissue-type plasminogen activator production.
46. 46. Wheelwright, S. M. (1991) Protein Purification: Design and Scale up of Downstream Processing, Hanser, New York, pp. 213-216.
47. 47. Gardell, S. J., Duong, L. T., Diehl, R. E., York, J. D., Hare, T. R., Register, R. B., Jacobs, J. W., Dixon, R. A. F. and Friedman, P. A. (1989) J. Biol. Chem., 264: 17947-17952. Isolation characterization, and cDNA cloning of a vampire bat salivary plasminogen activator.
48. 48. Binder, B. R., Spragg, J. and Austen, K. F. (1979) J. Biol. Chem., 254: 1998-2003. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.
49. 49. Allen, R. A. and Pepper, D. S. (1981) Thromb. Haemostas., 45: 43-50. Isolation and properties of human vascular plasminogen activator.
50. 50. Wallén, P., Bergsdorf, N. and Rånby, M. (1982) Biochim. Biophys. Acta., 719: 318-328. Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin.
51. 51. Kacian, D. L. and Harvey, R. C. (1985) Arch. Biochem. Biophys., 236: 354-369. Purification of plasminogen activator from Rous sarcoma virus-infected chick embryo fibroblast culture medium.
52. 52. Reagan, M. E., Robb, M., Bornstein, I. and Niday, E. G. (1985) Thromb. Res., 40: 1-9. Immunoaffinity purification of tissue plasminogen activator from serum-supplemented medium using monoclonal antibodies.
53. 53. Harakas, N. K., Schaumann, J. P., Connolly, D. T., Wittwer, A. J., Olander, J. V., Feder, J. (1988) Biotechnol. Progress, 4: 149-158. Large-scale purification of tissue-type plasminogen activator from cultured human cells.
54. 54. Rijken, D. C. and Collen, D. (1981) J. Biol. Chem., 256: 7035-7041. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.
55. 55. Heinrikson, R. L. and Tomasselli, A. G. (1991) In Purification and Analysis of Recombinant Proteins, Seetharam, S. and Sharma, S. K., editors, Marcel Dekker, New York, pp. 3-28. Purification and characterization of recombinant proteins: opportunities and challenges.
56. 56. Tolbert, W. R. (1988) World Biotech Report 1988, Online Publications, London, pp. 119-125. The economics of manufacture - will the price come down?
57. 57. Garrido, F., Banerjee, U. C., Chisti, Y. and Moo-Young, M. (1994) Bioseparation, 4: 319-328. Disruption of a recombinant yeast for the release of β-galactosidase.
58. 58. Sarmientos, P., Duchesne, M., Denèfle, P., Boiziau, J., Fromage, N., Delporte, N., Parker, F., Lelièvre, Y., Mayaux, J. -F. and Cartwright, T. (1989) Biotechnology, 7: 495-501. Synthesis and purification of active human tissue plasminogen activator from Escherichia coli.
59. 59. Anicetti, V. R., Keyt, B. A. and Hancock, W. S. (1989) Trends Biotechnol., 7(12): 342-349. Purity analysis of protein pharmaceuticals produced by recombinant DNA technology.
60. 60. Wiebe, M. E., Becker, F., Lazar, R., May, L., Casto, B., Semense, M., Fautz, C., Garnick, R., Miller, C., Masover, G., Bergmann, D. and Lubiniecki, A. S. (1989) In Advances in Animal Cell Biology and Technology for Bioprocesses, Spier, R. E., Griffiths, J. B., Stephenne, J. and Crooy, P. J., editors, Butterworths, London, pp. 68-71. A multifaceted approach to assure that recombinant tPA is free of adventitious virus.
61. 61. Garg, V. K., Costello, M. A. C. and Czuba, B. A. (1991) In Purification and Analysis of Recombinant Proteins, Seetharam, S. and Sharma, S. K., editors, Marcel Dekker, New York, pp. 29-54. Purification and production of therapeutic grade proteins.
62. 62. Bluestone, M. (1992) Biotechnology, 10: 480. tPA falls short once again.
63. 63. Piérard, L., Quintana, L. G., Reff, M. E. and Bollen, A. (1989) In Advances in Animal Cell Biology and Technology for Bioprocesses, Spier, R. E., Griffiths, J. B., Stephenne, J. and Crooy, P. J., editors, Butterworths, London, pp. 475-480. Secretion of recombinant hybrid plasminogen activator by mouse myeloma cells.
64. 64. Noll, G., Lämmle, B. and Duckert, F. (1985) Thromb. Res., 37: 529-532. Treatment with stanozolol before thrombolysis in patients with arterial occlusions.